C12N 2840/00
Vectors comprising a special translation-regulating system
C12N2840/00 (Vectors comprising a special translation-regulating system) appears on 1,645 US grants and 2,578 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,645
- Published applications
- 2,578
- Assignees
- 1,038
- Inventors
- 4,573
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 21 | 0 |
| 1997 | 39 | 0 |
| 1998 | 59 | 0 |
| 1999 | 43 | 0 |
| 2000 | 62 | 0 |
| 2001 | 64 | 16 |
| 2002 | 58 | 112 |
| 2003 | 68 | 199 |
| 2004 | 50 | 164 |
| 2005 | 47 | 147 |
| 2006 | 62 | 131 |
| 2007 | 65 | 76 |
| 2008 | 55 | 76 |
| 2009 | 50 | 87 |
| 2010 | 51 | 83 |
| 2011 | 48 | 86 |
| 2012 | 42 | 71 |
| 2013 | 54 | 62 |
| 2014 | 55 | 68 |
| 2015 | 53 | 72 |
| 2016 | 61 | 66 |
| 2017 | 57 | 91 |
| 2018 | 48 | 91 |
| 2019 | 44 | 95 |
| 2020 | 60 | 79 |
| 2021 | 66 | 105 |
| 2022 | 57 | 122 |
| 2023 | 43 | 108 |
| 2024 | 52 | 126 |
| 2025 | 60 | 125 |
| 2026 | 34 | 120 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2840/20Translation of more than one cistronIndexing code1,169
- C12N 2840/44Being a specific part of the splice mechanismIndexing code395
- C12N 2840/10Regulates levels of translationIndexing code167
- C12N 2840/007Cell or tissue specificIndexing code73
- C12N 2840/80From vertebratesIndexing code50
- C12N 2840/002Controllable or inducibleIndexing code47
- C12N 2840/60From virusesIndexing code38
- C12N 2840/55From bacteriaIndexing code25
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias22 Sep 2026US 12,742,171 B2Dna Twopointo Inc.
- Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy15 Sep 2026US 12,735,723 B2Research Institute At Nationwide Children's Hospital
- Multi-transgenic pig for Xenotransplantation25 Aug 2026US 12,714,077 B2Revivicor, Inc.
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene8 Oct 2026US 2026/0308549 A1Precision BioSciences, Inc.
- Method8 Oct 2026US 2026/0308574 A1Sania Tx Ltd
- Expression cassette coding for vascular endothelial growth factor8 Oct 2026US 2026/0308618 A1Cornell University
Most cited
By later US patents
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Isolation of exogenous recombinant proteins from the milk of transgenic mammals500US 4,873,316 ABiogen, Inc. · 1989
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- Preparation of functional human factor VIII in mammalian cells using methotrexate based selection276US 4,965,199 AGenentech, Inc. · 1990
- Transgenic bovine266US 5,741,957 APharming B.V. · 1998